BRPI0510570A - composição de vacina - Google Patents

composição de vacina

Info

Publication number
BRPI0510570A
BRPI0510570A BRPI0510570-6A BRPI0510570A BRPI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A BR PI0510570 A BRPI0510570 A BR PI0510570A
Authority
BR
Brazil
Prior art keywords
vaccine composition
antigen
vaccine
eso
saponin
Prior art date
Application number
BRPI0510570-6A
Other languages
English (en)
Inventor
Vincent Brichard
Remi M Palmantier
Melinda Meaders
Claudine Elvire Marie Bruck
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0510570A publication Critical patent/BRPI0510570A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO DE VACINA. A presente invenção fornece novas formulações de vacina para o tratamento de antígenos do câncer. A vacina compreende um antígeno MAGE-3 modificado, um antígeno NY-ESO- 1, e um adjuvante compreendendo uma saponina e um oligonucleotídeo imunoestimulador.
BRPI0510570-6A 2004-05-04 2005-05-02 composição de vacina BRPI0510570A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409940.4A GB0409940D0 (en) 2004-05-04 2004-05-04 Vaccine
PCT/EP2005/004956 WO2005105139A2 (en) 2004-05-04 2005-05-02 Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy

Publications (1)

Publication Number Publication Date
BRPI0510570A true BRPI0510570A (pt) 2007-11-20

Family

ID=32482653

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510570-6A BRPI0510570A (pt) 2004-05-04 2005-05-02 composição de vacina

Country Status (16)

Country Link
US (1) US20070243196A1 (pt)
EP (1) EP1755657A2 (pt)
JP (1) JP2007536326A (pt)
CN (1) CN1980691A (pt)
AU (1) AU2005237256A1 (pt)
BR (1) BRPI0510570A (pt)
CA (1) CA2564470A1 (pt)
GB (1) GB0409940D0 (pt)
IL (1) IL178681A0 (pt)
MA (1) MA28639B1 (pt)
MX (1) MXPA06012723A (pt)
NO (1) NO20065480L (pt)
NZ (1) NZ550967A (pt)
RU (1) RU2006138283A (pt)
WO (1) WO2005105139A2 (pt)
ZA (1) ZA200608693B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137986A2 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals Sa Vaccination against cancer
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
WO2008089074A2 (en) * 2007-01-15 2008-07-24 Glaxosmithkline Biologicals Sa Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
CA2680914C (en) 2007-03-13 2019-06-18 University Of Zurich Monoclonal human tumor-specific antibody
BRPI0811228A2 (pt) 2007-05-24 2014-10-21 Glaxonsmithkline Biolog S A Composição liofilizada, e, métodos para produzir uma composição liofilizada e para produzir uma composição imunológica.
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
KR20120002534A (ko) 2009-03-17 2012-01-05 엠디엑스헬스 에스에이 유전자 발현의 향상된 검출
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US20130295091A1 (en) * 2011-01-10 2013-11-07 University Of Zurich Combination therapy including tumor associated antigen binding antibodies
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
HRP20211452T1 (hr) * 2013-05-14 2021-12-24 Zoetis Services Llc Novi cjepivni pripravci koji sadrže imunostimulacijske oligonukleotide
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
US20160030539A1 (en) * 2014-08-01 2016-02-04 Texas Tech University System Cancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
US11945851B2 (en) 2017-06-07 2024-04-02 The Wistar Institute Of Anatomy And Biology MAGE-A vaccines and methods of treatment using the same
WO2019061297A1 (zh) 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
EP0882246A1 (en) * 1996-02-23 1998-12-09 BRITISH TELECOMMUNICATIONS public limited company Optical interconnect
CN1227360C (zh) * 1998-02-05 2005-11-16 史密丝克莱恩比彻姆生物有限公司 Mage家族肿瘤相关抗原衍生物及其编码核酸序列
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens

Also Published As

Publication number Publication date
CN1980691A (zh) 2007-06-13
WO2005105139A2 (en) 2005-11-10
US20070243196A1 (en) 2007-10-18
ZA200608693B (en) 2010-01-27
GB0409940D0 (en) 2004-06-09
IL178681A0 (en) 2007-02-11
MXPA06012723A (es) 2007-02-14
WO2005105139A3 (en) 2006-04-13
RU2006138283A (ru) 2008-06-10
NZ550967A (en) 2009-01-31
AU2005237256A1 (en) 2005-11-10
MA28639B1 (fr) 2007-06-01
EP1755657A2 (en) 2007-02-28
CA2564470A1 (en) 2005-11-10
JP2007536326A (ja) 2007-12-13
NO20065480L (no) 2006-11-28

Similar Documents

Publication Publication Date Title
BRPI0510570A (pt) composição de vacina
CY1116904T1 (el) Εμβολιο
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
TW200700079A (en) Composition
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
CO6331297A2 (es) Composiciones adyuvantes novedosas
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
BRPI0608815A8 (pt) Composições de anticorpo anti-ctla-4
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
CR10559A (es) Vacuna de influenza
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
CL2019002876A1 (es) Síntesis de triterpeno-saponina, intermediarios y combinaciones adyuvantes.
BR112012013329A2 (pt) composição oral e método para o tratamento de uma doença ou condição do tecido mole da cavidade oral
EA201001478A1 (ru) Вакцина
GB2444676A (en) Adjuvanted vaccine
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
TW200637573A (en) Peptide for delivery of mucosal vaccines
TNSN07187A1 (en) Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. their use in the treatment of cancer
UY31510A1 (es) Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
BR112021017691A2 (pt) Formulações imunogênicas para o tratamento do câncer
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
BRPI0811459A8 (pt) Preparação virossômica, uso de uma preparação virossômica, kit, e, métodos para vacinar um ser humano contra infecções de influenza, e para vacinar indivíduos mamíferos contra infecções da influenza

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.